Organized by: Oncology Center of Biomedical Education and Research
Oncology Unit, 3rd Department of Medicine, Medical School of Athens

4th LUNG CANCER Network

«From the Bench to the Bedside»

January 15-16, 2016, Hilton Athens, Greece

Accreditation from:
Panhellenic Medical Association

Under the auspices of:

ESMO
European Society for Medical Oncology

IASLC
International Association for the Study of Lung Cancer

etop
Information | Research

SCIENTIFIC PROGRAM
The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, holds promise for personalized treatment of these patients that would provide more effective and less toxic therapeutic approaches, improving the prognosis of the patients with thoracic malignancies. On the other hand, the immense bulk and the rapid recycling of the new information makes difficult its understanding, evaluation and interpretation by the clinicians. Therefore, the «translation» of our recently acquired knowledge from the lab bench to the bedside is neither smooth nor is it without obstructions, due to the existing «gaps» in our understanding and the often contradictory «signals» from clinical trials.

The success of our three previous meetings has prompted us to organize the 4th Lung Cancer Network «From the Bench to the Bedside». Our aim is to narrow the distance between the bench lab and the patient’s bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists. Our multidisciplinary, international faculty will present the latest clinical data and provide treating physicians with practical information regarding the clinical significance of the histological, molecular and genetic profile of the tumor and how the implementation of targeted agents in the therapeutic algorithm changes the clinical practice of lung cancer patients.

Finally, we anticipate that our meeting, with the presence of our distinguished faculty, would provide the opportunity and motivation for discussions regarding the emerging therapies and set the pavement for the future research and strategies towards the personalized treatment of lung cancer patients.

We cordially welcome you all in Athens in January 15th and 16th 2016 for a stimulating, innovative and educational meeting.
Learning Objectives
At the end of our educational meeting, the participant will be able to:

• Acquaint with the new staging and pathology classification systems in lung cancer
• Recognize the clinical significance of molecular genotyping of lung cancer patients
• Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients
• Update of Immunotherapy strategies for lung cancer
• Discuss the optimal methodology of evaluation of response in the era of translational research
• Recognize the importance of a multidisciplinary approach to the care lung cancer patients

Topics

• New IASLC lung cancer staging system
• New WHO lung cancer pathology classification
• Neuroendocrine lung cancer update
• Thymic cancer update
• Tumor heterogeneity
• Prognostic and predictive tumor markers
• Molecular signaling of LC
• NSCLC driver oncogenes
• Immunotherapy
• Evaluation of response
• Masterprotocols in lung cancer.
• Agents related-toxicity management
• Newer generation TKIs inhibitors

Target Audience
The meeting is designed for medical, radiation and surgical oncologists, pathologists, chest physicians, scientists, residents-in-training, fellows and other health care professionals interested in the basic and clinical research as well as in the management of thoracic cancers.

CME Accreditation - Auspice
The content of the meeting will be submitted for CME accreditation and we will request the auspices of ESMO, IASLC and ETOP.

The Chairs of the Meeting

Professor Kostas Syrigos  
Professor Alex Adjei  
Professor Rolf Stahel
# Scientific Program

**FRIDAY January 15th 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Registrations</td>
<td></td>
</tr>
<tr>
<td>09:00-11:00</td>
<td><strong>Updates from 16th WCLC-IASLC (I)</strong></td>
<td>Fulden Yumuk, Giannis Gkiouzos</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Screening for lung cancer - update and the ways for implementation.</td>
<td>Nir Peled</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Thoracic surgery updates.</td>
<td>Ramón Rami-Porta</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Radiotherapy updates.</td>
<td>Françoise Mornex</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Medical oncology update.</td>
<td>Vali Papadimitrakopoulou</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:30-13:30</td>
<td><strong>Updates from 16th WCLC-IASLC (II)</strong></td>
<td>Kostas Zarogoulidis, Michalis Toubis</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Nursing updates.</td>
<td>Liz Darlison</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Global tobacco control updates.</td>
<td>Elif Dağli</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Supportive care updates.</td>
<td>Richard Booton</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Thoracic malignancies beyond NSCLC.</td>
<td>Fulden Yumuk</td>
</tr>
<tr>
<td>13:30-13:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:45-14:30</td>
<td><strong>Industry satellite symposium</strong></td>
<td>Kostas Syrigos, Paris Kosmidis</td>
</tr>
<tr>
<td>13:45-14:30</td>
<td>Predictive and prognostic biomarkers for the immune checkpoints inhibitors.</td>
<td>Rolf Staher</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Lunch break</td>
<td></td>
</tr>
<tr>
<td>16:30-18:00</td>
<td><strong>New WHO pathology classification of lung cancer</strong></td>
<td>Fred Hirsch, Christos Kittas</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td>Thymic cancer classification update.</td>
<td>Michael den Bakker</td>
</tr>
<tr>
<td>16:50-17:10</td>
<td>Squamous and undifferentiated tumors classification update.</td>
<td>Keith Kerr</td>
</tr>
<tr>
<td>17:10-17:30</td>
<td>Adenocarcinoma: classification and implications.</td>
<td>William Travis</td>
</tr>
<tr>
<td>17:30-17:50</td>
<td>Neuroendocrine tumor update.</td>
<td>Elisabeth Brambilla</td>
</tr>
<tr>
<td>17:50-18:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:00-18:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Chair/Presenter</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>18:30-20:00</td>
<td>Pathologist and clinician interaction</td>
<td>William Travis, Efstratios Patsouris</td>
</tr>
<tr>
<td>18:30-18:50</td>
<td>Cytology, small and liquid biopsies in lung cancer.</td>
<td>Keith Kerr</td>
</tr>
<tr>
<td>19:10-19:30</td>
<td>Tumor heterogeneity: impact on drug development.</td>
<td>Charles Swanton</td>
</tr>
<tr>
<td>19:30-19:50</td>
<td>Endpoints in clinical trials.</td>
<td>David Ettinger</td>
</tr>
<tr>
<td>19:50-20:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>20:00-20:45</td>
<td>Opening Ceremony</td>
<td>Alex Adjei, Kostas Symigos</td>
</tr>
<tr>
<td>20:00-20:15</td>
<td>Awards 2016</td>
<td>Paris Kosmidis, Rolf Stahel, Paul Bunn</td>
</tr>
<tr>
<td>20:15-20:45</td>
<td>Keynote lecture</td>
<td>Paul Bunn</td>
</tr>
<tr>
<td>20:45</td>
<td>Welcome cocktail</td>
<td></td>
</tr>
</tbody>
</table>

**SATURDAY January 16th 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:30</td>
<td>Oncogene driver NSCLC</td>
<td>Paul Bunn, Paris Kosmidis</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>EGFR TKIs state of art 2016.</td>
<td>David Ettinger</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>EML4-ALK TKIs state of art 2016.</td>
<td>Chandra Belani</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Other targetable oncogenes in lung cancer.</td>
<td>Alex Adjei</td>
</tr>
<tr>
<td>10:30-11:10</td>
<td>Evaluation of response</td>
<td>Enriqueta Felip, Kostas Symigos</td>
</tr>
<tr>
<td>10:30-10:50</td>
<td>RECIST criteria in the post-chemotherapy era.</td>
<td>Paul Bunn</td>
</tr>
<tr>
<td>10:50-11:10</td>
<td>Next generation sequencing (NGS) testing: when and for whom.</td>
<td>Gregory Riely</td>
</tr>
<tr>
<td>11:10-11:30</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Invited Lecture</td>
<td>Johan Vansteenkiste, Ioannis Boukovanas</td>
</tr>
<tr>
<td></td>
<td>Masterprotocols in lung cancer.</td>
<td>Fred Hirsch</td>
</tr>
</tbody>
</table>
12:00-13:30 **Optimal use of the driver oncogenes TKIs**  
Chair: Alex Adjei, Sofia Agelaki

12:00-12:20 Early stages NSCLC. Solange Peters
12:20-12:40 Integration of radiotherapy with TKIs treatment. Lucio Crinó
12:40-13:00 Management of TKI toxicities. Gregory Riely
13:00-13:20 Resistance to TKIs: molecular or clinical documentation? David Carbone
13:20-13:30 Discussion

13:30-16:00 Lunch break

16:00-17:00 **Molecular signature of lung cancer**  
Chair: Solange Peters, Vassilis Gorgoulis

16:00-16:15 The RAS/RAF pathway. Alex Adjei
16:15-16:30 The HER2. Enriqueta Felip
16:30-16:45 T790M inhibition. Rolf Stahel
16:45-17:00 Discussion

17:00-18:00 **Industry satellite symposium**  
**Sponsored by** Bristol-Myers Squibb  
Chair: Kostas Syrigos

Immuno oncology in lung cancer: changing the treatment paradigm. Solange Peters

18:00-18:30 Coffee break

18:30-20:30 **Immunotherapy**  
Chair: Lucio Crinó, Rolf Stahel

18:30-18:50 Immune activation and checkpoint inhibition. Vali Papadimitrakopoulou
18:50-19:10 Immune biomarkers and immune signature. Thorsten Füreder
19:10-19:30 Which target? Which molecule? Chandra Belani
19:30-19:50 Management of toxicities. Solange Peters
19:50-20:10 Integration of immunotherapy to current treatment options. Johan Vansteenkiste
20:10-20:30 Future strategies of lung cancer immunotherapy. Rolf Stahel

20:30 Closing ceremony
Adjei Alex  MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia, Chair in Cancer Medicine Senior, Vice President for Clinical Research, Roswell Park Cancer Institute, USA

Agelaki Sofia  Assistant Professor of Medical Oncology, University of Crete, Greece

Belani Chandra  MD, Miriam Beckner Distinguished Professor of Medicine, Penn State College of Medicine, Head, Lung Cancer Program, Penn State Hershey Cancer Institute, USA

Booton Richard  Dr, Consultant Respiratory Physician, Honorary Senior Lecturer in Respiratory Medicine Manchester Thoracic Oncology Centre, University Hospital of South Manchester, UK

Boukouvinas Ioannis  MD, PhD, Medical Oncologist, Head of Oncology Unit Bioclinic, Thessaloniki, Greece

Brambilla Elisabeth  Professor of Pathology, Grenoble University Hospital, University Joseph Fourier, Grenoble, France

Bunn Paul Jr  MD, Distinguished Professor and James Dudley Endowed Chair in Lung Cancer Research, University of Colorado Cancer Centre, Aurora, CO, USA

Carbone David  MD, PhD, Professor of Medicine, Director, James Thoracic Oncology Center, Barbara J. Bonner Chair in Lung Cancer Research, President, International Association for the Study of Lung Cancer (IASLC)

Crinò Lucio  Professor, Director, Department of Medical Oncology, University Hospital, Perugia, Italy

Dağlı Elif  Lecturer at Marmara University, Turkey

Darlison Liz  Director of Services and Consultant Nurse, Mesothelioma UK, University Hospitals of Leicester NHS Trust, The Glenfield Hospital, Leicester, UK

Den Bakker Michael  MD, PhD, Department of Pathology, Maasstad Hospital and Erasmus MC, Rotterdam, The Netherlands

Ettinger David  MD, Alex Grass Professor of Oncology, Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Felip Enriqueta  MD, PhD, Head, Thoracic Cancer Group, Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain, Associate Professor, Autonomous University of Barcelona (UAB)

Füreder Thorsten  Assistant Professor, Dr, Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria

Gkiozos Giannis  MD, PhD, FCCP, Pulmonologist, Clinical Fellow of Oncology Unite G’PP, Medical School of Athens, “Sotiria” Athens’ Chest Diseases Hospital, Greece

Gorgoulis Vassilis  Dr, MD, PhD, Professor-Director, Department of Histology-Embryology, Medical School, National Kapodistrian University of Athens, Greece

Hirsch Fred  MD, PhD, Professor of Medicine and Pathology, Associate Director of International Programs, University of Colorado Cancer Center, USA, CEO of IASLC

Kerr Keith  Professor, Consultant Pathologist, Department of Pathology, Aberdeen Royal Infirmary, Professor of Pulmonary Pathology, Aberdeen University Medical School, Forrestherhill, Aberdeen, Scotland, UK
Kittas Christos  Emeritus Professor of Histology and Embryology, School of Medicine, National and Kapodistrian University of Athens, Greece

Kosmidis Paris MD, Medical Oncologist, Head of 2nd Medical Oncology Department, “Hygeia” Hospital, Athens, Greece

Mornex Françoise MD, PhD, Radiation Oncologist, Centre Hospitalier Lyon Sud, Professor of Oncology at University Claude Bernard Lyon, France, Head of the Radiation Oncology Department, CHU de Lyon, France

Papadimitrakopoulou Vali MD, Jay and Lori Eisenberg Distinguished Professor, Professor of Medicine, Department of Thoracic/HN Medical Oncology, MD Anderson Cancer Center, Houston, USA

Patsouris Efstratios Professor, Dr, Chairman of 1st Department of Pathology, Medical School, University of Athens, Greece, Dean of School of Health Sciences

Peled Nir Professor, MD, PhD, FCCP, Pulmonologist and Medical Oncologist, Thoracic Cancer Unit, Davidoff Cancer Center, Israel, International Lung Cancer Association, Committee Chair, Prevention, Screening & Early Detection of Lung Cancer, IASLC

Peters Solange Dr, MD, PhD, Associate Professor, Chair Thoracic Malignances, Department of Oncology, University of Lausanne, Switzerland, Scientific Coordinator, European Thoracic Oncology Platform (ETOP)

Rami-Porta Ramón MD, Attending Thoracic Surgeon, Department of Thoracic Surgery, Hospital Universitari Mutua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain

Riely Gregory Associate Member, Memorial Sloan Kettering Cancer Centre, Associate Attending Physician, Memorial Hospital, Vice Chair, Department of Medicine, Associate Professor, Weill Cornell Medical College, USA

Stahel Rolf MD, Head of the Center for Lung and Thoracic Oncology, Senior Staff Physician, Clinic of Oncology, University Hospital of Zurich, Titular Professor of Medicine, University of Zurich, Switzerland

Swanton Charles MB, PhD, FRCP, FMedSci, Professor of Cancer Medicine, Chair in Personalised Medicine, Director of Lung Cancer Centre of Excellence, Senior Group Leader, Consultant Medical Oncologist, UK

Syrigos Kostas MD, PhD, Professor of Medicine and Medical Oncology, Head, 3rd Department of Medicine, “Sotiria” General Hospital, Athens School of Medicine, National and Kapodistrian University of Athens, Greece, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA

Travis William MD, Attending Thoracic Pathologist, Memorial Sloan Kettering Cancer Center, Professor of Pathology, Weill Medical College of Cornell University, New York, USA

Vansteenkiste Johan MD, PhD, Professor of Medicine, Catholic University Leuven, Head of Clinic, Respiratory Oncology Unit and Trial Unit, Department of Pneumology, University Hospital Gasthuisberg, Belgium

Yumuk Fulden MD, Marmara University, Medical School, Turkey

Zarogoulidis Kostas Professor in Pulmonology-Tuberculosis, Director of Pulmonary-Tuberculosis Clinic, Aristotle University of Thessaloniki “G. Papanikolaou” General Hospital, Greece
Meeting room - audiovisual - technical support
The meeting will take place at the “Hesperides” Hall and the meeting secretariat will operate at the “Hesperides” foyer during the sessions. The meeting room will be equipped with data video projectors, laser pointers etc for power point presentations. Technical support center will be available outside the “Hesperides” Hall. Technical staff will assist with the presentations. All speakers are kindly requested to submit their presentation at least one hour prior to their scheduled presentation.

Language
The official language of the congress is English.

CME Accreditation - Auspice
The content of the meeting will be submitted for CME accreditation. Accreditation will be received from the Panhellenic Medical Association. The meeting has requested the auspice of ESMO, IASLC and ETOP.

Name badges
All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

Certificate of Attendance
All registered participants who have attended at least 60% of the total scientific program will receive a certificate of attendance from the secretariat desk after the closing ceremony.
General information

Organized by the
Oncology Center of Biomedical Education and Research
Oncology Unit, 3rd Department of Medicine, Medical School of Athens

Meeting website
www.lungcancernetwork.eu

Meeting dates
January 15th & 16th, 2016

Meeting venue
Hilton Athens Hotel
46 Vassilissis Sofias Avenue
115 28 Athens, Greece
Tel.: 00 30 210 72 81 000

Conveniently situated in the heart of the city’s commercial district, and just 25 minutes from the airport using the Athens Metro, the Hilton Athens’ prime location and fabulous facilities make it the perfect spot for Athens meetings and exhibitions of all sizes.

Registration cost

<table>
<thead>
<tr>
<th>Type of registration</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doctors*</td>
<td>200€</td>
</tr>
<tr>
<td>Residents</td>
<td>100€</td>
</tr>
<tr>
<td>Nurses</td>
<td>free</td>
</tr>
<tr>
<td>Medical students</td>
<td>free</td>
</tr>
</tbody>
</table>

Registration cost includes:
• Admission to all sessions & exhibition area
• Meeting material
• Certificate of attendance
* ESMO & IASLC Members will receive a 20% discount

Meeting’s Secretariat

E.T.S. Events & Travel Solutions S.A.
El. Venizelou 154, 171 22 N. Smyrni - Athens, Greece
Tel.: +30 210 98 80 032, Fax: +30 210 98 81 303
E-mail: ets@otenet.gr, ets@events.gr, Website: www.events.gr